Visalytics
Visalytics
approved EB-2 (NIW)

Analytical Development Scientist

Pharmaceutical Science · China · 2025-05-24

Processing Time
337 days
Decision Date
2025-05-24
Location
Massachusetts
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop advanced analytical methods for gene therapy drug products using liquid chromatography-mass spectrometry and multi-color flow-based assays. This work focuses on improving treatment efficacy and ensuring the safety and precision of therapies for rare genetic diseases, cancers, and autoimmune disorders.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses public health challenges like rare genetic disorders and cancers, which are of significant national importance.

2 Well-Positioned to Advance the Endeavor Met

The petitioner's Ph.D., publication record, and NIH-funded research demonstrate his capacity to lead in pharmaceutical science.

3 On Balance, Beneficial to Waive Job Offer Met

The petitioner's expertise in biomanufacturing analytics supports U.S. competitiveness and health innovation urgency.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 9 peer-reviewed articles, a book chapter, and 141 citations. Evidence included 18 formal peer reviews for high-impact journals and proof of direct funding from the National Institutes of Health (NIH). The case satisfied all three Dhanasar prongs by demonstrating the clinical utility of his drug delivery methodologies in human trials.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Dependent
Grants
Judging Experience
Original Contributions
Clinical Deployment
Government Alignment

Similar Cases

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Illinois 535 days 2026-01-16
The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.
View Case

Scientist

Biotechnology · China

WeGreened EB-2 (NIW) approved
Florida 115 days 2025-03-03
The petitioner proposes to continue developing novel anticancer therapeutics derived from microorganisms using integrated applications of genome mining, biosynthetic engineering, and synthetic biology to identify novel pathways and enzymes that improve drug efficacy, scalability, and safety.
View Case

Scientist

Biotechnology · China

WeGreened EB-2 (NIW) approved
Maryland 5 days 2024-03-20
The petitioner proposes to continue her research on developing biomanufacturing processes to produce therapeutic moieties such as biologics, small molecules, and cell and gene therapies. Her work focuses on achieving optimal-quality treatments for diseases including cancer, inflammation, and rare diseases while expanding the availability of top-tier therapies through biomanufacturing innovations.
View Case

Research Scientist

Biotechnology · India

WeGreened EB-2 (NIW) approved
California 162 days 2025-12-23
The petitioner proposes to apply advanced molecular biology and multi-omics approaches to develop novel small-molecule inhibitors and RNA-based therapeutics. This work focuses on precisely targeting dysregulated signaling pathways to create therapeutic strategies for cancers, complex genetic disorders, and pathogen-induced infections.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-05-24.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 337 days
Criteria Met 3 / 3
Evidence Types 8

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist